A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World

Pranita D. Tamma, Yohei Doi, Robert A. Bonomo, J. Kristie Johnson, Patricia J. Simner

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Understanding the nuances of AmpC β-lactamase-mediated resistance can be challenging, even for the infectious diseases specialist. AmpC resistance can be classified into 3 categories: (1) inducible chromosomal resistance that emerges in the setting of a β-lactam compound, (2) stable derepression due to mutations in ampC regulatory genes, or (3) the presence of plasmid-mediated ampC genes. This review will mainly focus on inducible AmpC resistance in Enterobacteriaceae. Although several observational studies have explored optimal treatment for AmpC producers, few provide reliable insights into effective management approaches. Heterogeneity within the data and inherent selection bias make inferences on effective β-lactam choices problematic. Most experts agree it is prudent to avoid expanded-spectrum (ie, third-generation) cephalosporins for the treatment of organisms posing the greatest risk of ampC induction, which has best been described in the context of Enterobacter cloacae infections. The role of other broad-spectrum β-lactams and the likelihood of ampC induction by other Enterobacteriaceae are less clear. We will review the mechanisms of resistance and triggers resulting in AmpC expression, the species-specific epidemiology of AmpC production, approaches to the detection of AmpC production, and treatment options for AmpC-producing infections.

Original languageEnglish
Pages (from-to)1446-1455
Number of pages10
JournalClinical Infectious Diseases
Volume69
Issue number8
DOIs
Publication statusPublished - 27-09-2019

Fingerprint

Lactams
Enterobacteriaceae
Enterobacter cloacae
Selection Bias
Cephalosporins
Regulator Genes
Infection
Observational Studies
Communicable Diseases
Epidemiology
Plasmids
Mutation
Genes

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Tamma, Pranita D. ; Doi, Yohei ; Bonomo, Robert A. ; Johnson, J. Kristie ; Simner, Patricia J. / A Primer on AmpC β-Lactamases : Necessary Knowledge for an Increasingly Multidrug-resistant World. In: Clinical Infectious Diseases. 2019 ; Vol. 69, No. 8. pp. 1446-1455.
@article{a97bae44d5b542559b5069f0255bd21d,
title = "A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World",
abstract = "Understanding the nuances of AmpC β-lactamase-mediated resistance can be challenging, even for the infectious diseases specialist. AmpC resistance can be classified into 3 categories: (1) inducible chromosomal resistance that emerges in the setting of a β-lactam compound, (2) stable derepression due to mutations in ampC regulatory genes, or (3) the presence of plasmid-mediated ampC genes. This review will mainly focus on inducible AmpC resistance in Enterobacteriaceae. Although several observational studies have explored optimal treatment for AmpC producers, few provide reliable insights into effective management approaches. Heterogeneity within the data and inherent selection bias make inferences on effective β-lactam choices problematic. Most experts agree it is prudent to avoid expanded-spectrum (ie, third-generation) cephalosporins for the treatment of organisms posing the greatest risk of ampC induction, which has best been described in the context of Enterobacter cloacae infections. The role of other broad-spectrum β-lactams and the likelihood of ampC induction by other Enterobacteriaceae are less clear. We will review the mechanisms of resistance and triggers resulting in AmpC expression, the species-specific epidemiology of AmpC production, approaches to the detection of AmpC production, and treatment options for AmpC-producing infections.",
author = "Tamma, {Pranita D.} and Yohei Doi and Bonomo, {Robert A.} and Johnson, {J. Kristie} and Simner, {Patricia J.}",
year = "2019",
month = "9",
day = "27",
doi = "10.1093/cid/ciz173",
language = "English",
volume = "69",
pages = "1446--1455",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",

}

A Primer on AmpC β-Lactamases : Necessary Knowledge for an Increasingly Multidrug-resistant World. / Tamma, Pranita D.; Doi, Yohei; Bonomo, Robert A.; Johnson, J. Kristie; Simner, Patricia J.

In: Clinical Infectious Diseases, Vol. 69, No. 8, 27.09.2019, p. 1446-1455.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A Primer on AmpC β-Lactamases

T2 - Necessary Knowledge for an Increasingly Multidrug-resistant World

AU - Tamma, Pranita D.

AU - Doi, Yohei

AU - Bonomo, Robert A.

AU - Johnson, J. Kristie

AU - Simner, Patricia J.

PY - 2019/9/27

Y1 - 2019/9/27

N2 - Understanding the nuances of AmpC β-lactamase-mediated resistance can be challenging, even for the infectious diseases specialist. AmpC resistance can be classified into 3 categories: (1) inducible chromosomal resistance that emerges in the setting of a β-lactam compound, (2) stable derepression due to mutations in ampC regulatory genes, or (3) the presence of plasmid-mediated ampC genes. This review will mainly focus on inducible AmpC resistance in Enterobacteriaceae. Although several observational studies have explored optimal treatment for AmpC producers, few provide reliable insights into effective management approaches. Heterogeneity within the data and inherent selection bias make inferences on effective β-lactam choices problematic. Most experts agree it is prudent to avoid expanded-spectrum (ie, third-generation) cephalosporins for the treatment of organisms posing the greatest risk of ampC induction, which has best been described in the context of Enterobacter cloacae infections. The role of other broad-spectrum β-lactams and the likelihood of ampC induction by other Enterobacteriaceae are less clear. We will review the mechanisms of resistance and triggers resulting in AmpC expression, the species-specific epidemiology of AmpC production, approaches to the detection of AmpC production, and treatment options for AmpC-producing infections.

AB - Understanding the nuances of AmpC β-lactamase-mediated resistance can be challenging, even for the infectious diseases specialist. AmpC resistance can be classified into 3 categories: (1) inducible chromosomal resistance that emerges in the setting of a β-lactam compound, (2) stable derepression due to mutations in ampC regulatory genes, or (3) the presence of plasmid-mediated ampC genes. This review will mainly focus on inducible AmpC resistance in Enterobacteriaceae. Although several observational studies have explored optimal treatment for AmpC producers, few provide reliable insights into effective management approaches. Heterogeneity within the data and inherent selection bias make inferences on effective β-lactam choices problematic. Most experts agree it is prudent to avoid expanded-spectrum (ie, third-generation) cephalosporins for the treatment of organisms posing the greatest risk of ampC induction, which has best been described in the context of Enterobacter cloacae infections. The role of other broad-spectrum β-lactams and the likelihood of ampC induction by other Enterobacteriaceae are less clear. We will review the mechanisms of resistance and triggers resulting in AmpC expression, the species-specific epidemiology of AmpC production, approaches to the detection of AmpC production, and treatment options for AmpC-producing infections.

UR - http://www.scopus.com/inward/record.url?scp=85071146501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071146501&partnerID=8YFLogxK

U2 - 10.1093/cid/ciz173

DO - 10.1093/cid/ciz173

M3 - Review article

C2 - 30838380

AN - SCOPUS:85071146501

VL - 69

SP - 1446

EP - 1455

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 8

ER -